Treatment of Obesity with GLP-1RAs GLP-1RAs enhance satiety, decrease food consumption, and delay gastric emptying, while also promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner.92,93 Subcutaneous administration of liraglutide (3 mg daily) and semaglutide (2.4 mg weekly) has been approved for obesity management
NASH Nonalcoholic steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease that is characterized by liver steatosis, inflammation and fibrosis
Additional sensitivity analysis compared new GLP-1 RAs users with individuals commencing other second-line antihyperglycemic treatments, including Sulfonylureas, dipeptidyl peptidase-4 inhibitors, or Pioglitazone
Tricky to Treat Glial cells perform many essential functions
The FAQs do not indicate how the central processor will determine if this exclusion applies, or whether a plan coverage determination that the GLP-1 will not be covered under the plan will be deemed sufficient to indicate it does not apply